Details of the Drug
General Information of Drug (ID: DM3BOQA)
| Drug Name |
Beta-L-fucose
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
BETA-L-FUCOSE; beta-L-fucopyranose; 6-deoxy-beta-L-galactopyranose; beta-L-Fuc; 6-DEOXY-BETA-L-GALACTOSE; UNII-3MLV1G4S4M; 3MLV1G4S4M; 13224-93-6; (2S,3S,4R,5S,6S)-6-methyloxane-2,3,4,5-tetrol; FUL; MFB; 1rdj; 1ofz; AC1L9H0R; SCHEMBL1259620; CHEBI:42589; beta-L-Galactopyranose, 6-deoxy-; ZINC1532813; AKOS024286278; DB03283; CJ-24261; ST092737; AJ-26816; C20836; A817260; WURCS=2.0/1,1,0/[a1221m-1b_1-5]/1/
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 164.16 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -2.1 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 4 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


